March-In Rights Likely A Slow Trot at Best | Capitol Street

Published On: 02/08/2022 ▪

March-In Rights Likely A Slow Trot at Best

Xtandi’s High US Price Reinvigorates Government IP Rights Debate

Access memo here

View More Posts

One More Time? PHE Extension In the Cards
Published On: 10/27/2022
Cancer Moonshot 2.0: What’s Different This Time?
Published On: 10/24/2022
Oncology Care Value Based Care Emerges
Published On: 10/21/2022
Biden Signs EO Drug Pricing
Published On: 10/14/2022
FTC Indicates PBM Law Enforcement & Market Rule
Published On: 10/10/2022
PHE Scheduled End Mid-January 2023
Published On: 10/04/2022
5 Year FDA User Fee Authorization
Published On: 09/29/2022
CMS Requires Broker Call Recording Oct. 1
Published On: 09/27/2022
Mental Health Bill Increases Psychiatry Slots
Published On: 09/22/2022
FDA User Fees Likely Pass With Budget Next Week
Published On: 09/22/2022

What insights can we share with you?

Contact Info

900 19th Street Northwest
Washington, DC 20006
United States
team@capitol-street.com

PastedGraphic-26